Literature DB >> 19890129

Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension.

Stephen L Archer1, Evangelos D Michelakis.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19890129     DOI: 10.1056/NEJMct0904473

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  59 in total

Review 1.  Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies.

Authors:  Stephen L Archer; E Kenneth Weir; Martin R Wilkins
Journal:  Circulation       Date:  2010-05-11       Impact factor: 29.690

Review 2.  Update on pulmonary hypertension 2009.

Authors:  Mark T Gladwin; Hossein-Ardeschir Ghofrani
Journal:  Am J Respir Crit Care Med       Date:  2010-05-15       Impact factor: 21.405

Review 3.  Advances in targeting cyclic nucleotide phosphodiesterases.

Authors:  Donald H Maurice; Hengming Ke; Faiyaz Ahmad; Yousheng Wang; Jay Chung; Vincent C Manganiello
Journal:  Nat Rev Drug Discov       Date:  2014-04       Impact factor: 84.694

4.  Sildenafil improves renal function in patients with pulmonary arterial hypertension.

Authors:  David J Webb; Jean-Luc Vachiery; Lie-Ju Hwang; Julie O Maurey
Journal:  Br J Clin Pharmacol       Date:  2015-05-19       Impact factor: 4.335

5.  Sildenafil exposure and hemodynamic effect after Fontan surgery.

Authors:  Robert D Tunks; Piers C A Barker; Daniel K Benjamin; Michael Cohen-Wolkowiez; Gregory A Fleming; Matthew Laughon; Jennifer S Li; Kevin D Hill
Journal:  Pediatr Crit Care Med       Date:  2014-01       Impact factor: 3.624

6.  Sildenafil for pulmonary hypertension in ARDS: a new pleasant effect?

Authors:  Lluis Blanch; Guillermo M Albaiceta
Journal:  Intensive Care Med       Date:  2010-02-04       Impact factor: 17.440

7.  Phosphodiesterase type 2 distribution in the guinea pig urinary bladder.

Authors:  M S Rahnama'i; R Hohnen; Ph E V Van Kerrebroeck; G A van Koeveringe
Journal:  World J Urol       Date:  2014-12-06       Impact factor: 4.226

Review 8.  Pulmonary arterial hypertension: pathogenesis and clinical management.

Authors:  Thenappan Thenappan; Mark L Ormiston; John J Ryan; Stephen L Archer
Journal:  BMJ       Date:  2018-03-14

Review 9.  The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension.

Authors:  Jeremy A Falk; Kiran J Philip; Ernst R Schwarz
Journal:  Vasc Health Risk Manag       Date:  2010-05-06

Review 10.  Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension.

Authors:  Gautam V Ramani; Myung H Park
Journal:  Drug Des Devel Ther       Date:  2010-05-25       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.